DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 1 Paul Choi - 1 Arvinas - 1 Choi - 1 — CNBC's Michael Bloom - 1
Top related locs:
Top related orgs:
Biotech - 1 Arvinas - 1 Pfizer - 1

Search resuls for: "Paul Choi"


4 mentions found


☆ Goldman gives this innovative cancer-fighting biotech nearly 70% upside
  + stars: | 2024-02-01 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +1 min
Biotech company Arvinas could see its shares rally from a potential medium- to long-term commercial opportunity, according to Goldman Sachs. The firm initiated coverage on Arvinas with a buy rating and price target of $70. That suggests 68.7% upside potential from where shares closed Wednesday. According to analyst Paul Choi, breast cancer drug vepdegestrant (ARV-471), which is being co-developed by Arvinas and Pfizer , presents an "underappreciated" commercial opportunity. Arvinas has a "differentiated protein degrader platform that could expand several major markets," Choi wrote in a Thursday note.
Persons: Goldman Sachs, Paul Choi, Arvinas, Choi, — CNBC's Michael Bloom Organizations: Biotech, Arvinas, Pfizer
☆ Goldman Sachs upgrades Vir Biotechnology, says shares can more than double post-Covid
  + stars: | 2023-02-21 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Vir Biotechnology shares can more than double going forward, according to Goldman Sachs. Called VIR-2482, the antibody treatment offers users broad protection against flu strains that could last the entirety of a flu season, according to Vir. Still, the analyst expects that shares can surge this year on a post-Covid story, rising more than 105% to the analyst's 12-month price target of $53. The price target was raised from $41. Vir shares are about 5% higher during Tuesday premarket trading.
☆ Buy this little-known and underappreciated biopharma stock with nearly 60% upside, Goldman Sachs says
  + stars: | 2022-12-14 | by ( Samantha Subin | ) www.cnbc.com   time to read: +1 min
Investors should consider putting money in Xenon Pharmaceuticals , a biopharma stock poised to rally as Wall Street gains more clarity on its drug to treat epilepsy, Goldman Sachs says. The stock, he said, could jump 58% from Tuesday's close, given the bank's price target, and offers investors "innovation and blockbuster potential in an overlooked neuro category." Those gains would come even after a solid 24% gain this year and near 8% gain this month." And Xenon has solid balance sheet, Choi said. "Although pricing power will likely be limited, we think [the drug's] differentiated profile ... combined with good launch execution portends blockbuster FOS sales in the mostly generic epilepsy category," Choi wrote.
☆ Goldman says buy this under-the-radar biopharma stock expected to rally nearly 80%
  + stars: | 2022-10-20 | by ( Samantha Subin | ) www.cnbc.com   time to read: +1 min
This little-known California-based biopharmaceutical stock can see its shares rally nearly 80% in the near term, according to Goldman Sachs. Shares of the company's stock were up more than 5% in trading Thursday on the back of Choi's call. The analyst also sees promise in the company's pipeline of Bruton's tyrosine kinase inhibitor drugs, currently in the works to treat a slew of conditions including some forms of lymphoma and potentially multiple sclerosis. The bank's price target suggests shares can soar another 78% from Wednesday's close. "We are broadly bullish on GOSS's pipeline and view the risk/reward profile at current levels as favorable," he said.
0 next >>
Total: 4